Correlations between TBL1XR1 and recurrence of colorectal cancer

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Liu, Hongda ^a   Xu, Yunfei ^a   Zhang, Qun ^b   Li, Kangshuai ^a   Wang, Dawei ^c   Li, Shuo ^d   Ning, Shanglei ^a   Yang, Hui ^e   Shi, Weichen ^e   Liu, Zhaochen ^a   Chen, Yuxin ^a  

^a SHANDONG UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d BEIJING 302 HOSPITAL   (China)

^e THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CELL RECEPTOR; CTNNB1 PROTEIN, HUMAN; NUCLEAR PROTEIN; REPRESSOR PROTEIN; TBL1XR1 PROTEIN, HUMAN; TUMOR MARKER;

AGED; CANCER STAGING; COHORT ANALYSIS; COLORECTAL TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER TUMOR; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR CELL LINE; TUMOR RECURRENCE;

AGED; BETA CATENIN; BIOMARKERS, TUMOR; CELL LINE, TUMOR; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 85015340777     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep44275     Document Type: Article

References (28)

1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer 136, E359-386, doi: 10.1002/ijc.29210 (2015).
2. Cunningham, D. et al. Colorectal cancer. Lancet (London, England) 375, 1030-1047, doi: 10.1016/s0140-6736(10)60353-4 (2010).
3. Kriza, C., Emmert, M., Wahlster, P., Niederlander, C. & Kolominsky-Rabas, P. Cost of illness in colorectal cancer: an international review. Pharmaco Economics 31, 577-588, doi: 10.1007/s40273-013-0055-4 (2013).
4. Pritchard, C. C. & Grady, W. M. Colorectal cancer molecular biology moves into clinical practice. Gut 60, 116-129, doi: 10.1136/ gut.2009.206250 (2011).
5. Li, X. et al. Transducin (beta)-like 1 X-linked receptor 1 promotes proliferation and tumorigenicity in human breast cancer via activation of beta-catenin signaling. Breast cancer research: BCR 16, 465, doi: 10.1186/s13058-014-0465-z (2014).
6. Wang, J. et al. TBLR1 is a novel prognostic marker and promotes epithelial-mesenchymal transition in cervical cancer. British journal of cancer 111, 112-124, doi: 10.1038/bjc.2014.278 (2014).
7. Wu, X. et al. Nuclear TBLR1 as an ER corepressor promotes cell proliferation, migration and invasion in breast and ovarian cancer. American journal of cancer research 6, 2351-2360 (2016).
8. Daniels, G. et al. Cytoplasmic, full length and novel cleaved variant, TBLR1 reduces apoptosis in prostate cancer under androgen deprivation. Oncotarget, doi: 10.18632/oncotarget.9005 (2016).
9. Perissi, V. et al. TBL1 and TBLR1 phosphorylation on regulated gene promoters overcomes dual CtBP and NCoR/SMRT transcriptional repression checkpoints. Molecular cell 29, 755-766, doi: 10.1016/j.molcel.2008.01.020 (2008).
10. Soo-Yeon, P. et al. SUMOylation of TBL1 and TBLR1 promotes androgen-independent prostate cancer cell growth. Oncotarget, doi: 10.18632/oncotarget.9002 (2016).
11. Zhou, Q. et al. Transducin (beta)-like 1 X-linked receptor 1 promotes gastric cancer progression via the ERK1/2 pathway. Oncogene, doi: 10.1038/onc.2016.352 (2016).
12. Liu, F., He, Y. & Cao, Q. TBL1XR1 Is Highly Expressed in Gastric Cancer and Predicts Poor Prognosis. 2016, 2436518 (2016).
13. Choi, H. K. et al. Reversible SUMOylation of TBL1-TBLR1 regulates beta-catenin-mediated Wnt signaling. Molecular cell 43, 203-216, doi: 10.1016/j.molcel.2011.05.027 (2011).
14. Korinek, V. et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science (New York, NY.) 275, 1784-1787 (1997).
15. Morin, P. J. et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (New York, NY.) 275, 1787-1790 (1997).
16. van de Wetering, M. et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111, 241-250 (2002).
17. Siegel, R. et al. Cancer treatment and survivorship statistics, 2012. CA: a cancer journal for clinicians 62, 220-241, doi: 10.3322/ caac.21149 (2012).
18. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA: a cancer journal for clinicians 62, 10-29, doi: 10.3322/caac.20138 (2012).
19. Weitz, J. et al. Colorectal cancer. Lancet (London, England) 365, 153-165, doi: 10.1016/s0140-6736(05)17706-x (2005).
20. Bacolod, M. D. & Barany, F. Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. Annals of surgical oncology 18, 3694-3700, doi: 10.1245/s10434-011-1615-5 (2011).
21. Liu, H. et al. Prognostic significance of USP33 in advanced colorectal cancer patients: new insights into beta-arrestin-dependent ERK signaling. Oncotarget, doi: 10.18632/oncotarget.13219 (2016).
22. Chen, S. P. et al. Transducin beta-like 1 X-linked receptor 1 suppresses cisplatin sensitivity in nasopharyngeal carcinoma via activation of NF-kappaB pathway. Molecular cancer 13, 195, doi: 10.1186/1476-4598-13-195 (2014).
23. El-Bahrawy, M., Poulsom, R., Rowan, A. J., Tomlinson, I. T. & Alison, M. R. Characterization of the E-cadherin/catenin complex in colorectal carcinoma cell lines. International journal of experimental pathology 85, 65-74, doi: 10.1111/j.0959-9673.2004.0371.x (2004).
24. Fielding, L. P. et al. Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). Journal of gastroenterology and hepatology 6, 325-344 (1991).
25. Guo, S. et al. Hepatoma-derived growth factor: a novel prognostic biomarker in intrahepatic cholangiocarcinoma. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 36, 353-364, doi: 10.1007/s13277-014-2651-0 (2015).
26. Rosenbluh, J. et al. beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151, 1457-1473, doi: 10.1016/j.cell.2012.11.026 (2012).
27. Cadigan, K. M. Wnt/beta-catenin signaling: turning the switch. Developmental cell 14, 322-323, doi: 10.1016/j.devcel.2008.02.006 (2008).
28. Pan, C. et al. Cadmium is a potent inhibitor of PPM phosphatases and targets the M1 binding site. Scientific reports 3, 2333, doi: 10.1038/srep02333 (2013).